Pfizer Inc. CEO Albert Bourla has been talking for the past few weeks about creating a vaccine to control the omicron variant. Now the company, with partner Biontech SE, has initiated a clinical study of its new candidate by testing it in healthy adults. Bourla has said the company can adapt its vaccine to new variants in under three months and could have one ready to go in March if necessary.
Despite success in other parts of the world, Opko Health Inc. and Pfizer Inc. are still struggling to gain U.S. FDA approval for the recombinant human growth hormone somatrogon in treating pediatric patients, drawing a complete response letter (CRL) with their BLA. The delay caused by the setback gives Skytrofa (lonapegsomatropin) from Ascendis Pharma A/S a chance to charge even further ahead in the pediatric market.
Fresh data about vaccines by Valneva SE and the Gamaleya Research Institute show strength against COVID-19’s omicron variant. The new results helped continue a worldwide race to create, approve and distribute vaccines to fight the pandemic.
Ceptur Therapeutics Inc. has completed a $75 million series A financing to develop targeted oligonucleotide therapies based on its U1 adaptor technology. The adaptors are bivalent oligonucleotides designed to engage sequence-specific mRNA and the U1 small nuclear ribonuclear protein that regulates transcription and splicing. The therapeutics are for controlling gene expression at the pre-mRNA level within the nucleus.
The FDA clapped a clinical hold on the IND for a clinical trial of Dyne Therapeutics Inc.’s DYNE-251 for treating Duchenne muscular dystrophy in patients amenable to skipping exon 51. The agency is asking for more clinical and non-clinical information on the therapy. A response, including data from existing and ongoing studies in the second quarter of 2022, is expected to be filed to the FDA sometime in mid-2022, Dyne said.
The U.S. Center for Medicare & Medicaid Services (CMS) opened a 30-day comment window on its proposed national coverage determination (NCD) to limit Medicare access to monoclonal antibodies targeting amyloid beta in Alzheimer’s disease (AD) only in clinical trials. Biogen Inc., clearly the target, along with its AD treatment Aduhelm (aducanumab), was among the first to respond.
The pandemic has forced pharma and biotech to be more agile to better navigate the obstacles and still find success. Supply chain gaps are part of the problem, as are clinical trial delays. Yet the industry has successfully forged ahead in the past year to produce the seven drugs Clarivate believes in the next five years will each earn more than $1 billion annually.
The deals continued to flow during day two of the J.P. Morgan Healthcare Conference. Privately held Arrakis Inc., which specializes in aiming at small-molecule RNA targets, primarily cancers, has signed onto a collaboration with Amgen Inc. that could bring in billions in future payments should it hit all the milestones and program options are exercised. Dren Bio Inc., meanwhile, will collaborate with Pfizer Inc. to develop bispecific antibodies for oncology targets. Dren could receive more than $1 billion in the deal that includes a $25 million in cash up-front payment from Pfizer.
The pandemic has forced pharma and biotech to be more agile to better navigate the obstacles and still find success. Supply chain gaps are part of the problem, as are clinical trial delays. Yet the industry has successfully forged ahead in the past year to produce the seven drugs Clarivate believes in the next five years will each earn more than $1 billion annually.
Century Therapeutics Inc.’s $3.25 billion deal with Bristol Myers Squibb Co. (BMS) was the largest of four billion-dollar-plus agreements announced Dec. 10, piggybacking on a busy week that includes the start of the 40th annual J.P. Morgan Healthcare Conference.
